NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The 2011 pipeline shows strong interest in immunotherapy, which makes up 42% of products in development. Advancements in clinical trials and key partnerships are increasing exposure of this class. In this largely stable market, areas of innovation exist with nasal antihistamine/corticosteroid combinations remaining highly anticipated, while a number of novel targeted therapies raise skepticism.
Features and benefits
* Assessment of the allergic rhinitis pipeline, drawing out trends by class and the potential to address unmet needs
* Analysis of clinical trial design, highlighting innovation and anticipated future changes, with a focus on recent developments in immunotherapy
* Discussion of novel early stage approaches and the future of treatment in allergic rhinitis, with insight from key opinion leaders
Datamonitor has identified 60 products in development for allergic rhinitis. The late-stage pipeline is heavily skewed towards immunotherapy, which makes up 12 of 13 Phase III products. Immunotherapy shows the greatest innovation, with considerable change to clinical trials, and increased focus on sublingual tablet franchises.
Discussions with key opinion leaders reveal a largely stable market for symptomatic treatment; however, areas of innovation exist, such as the development of combination products. Analysis of comparator therapies Highlights areas of unmet need.
A number of novel targeted therapies are moving through the pipeline, and two CRTH2 antagonists have reached Phase II. Key opinion leaders express skepticism over their clinical viability, with efficacy expected to fall short of established treatment classes. However, they may find a place in the treatment of select groups of patients.
Your key questions answered
* Which characteristics of symptomatic treatments can be improved upon, and what would it take to create a new gold standard?
* What are the driving forces behind allergic rhinitis clinical trial design and how has it evolved?
* To what extent will the growing investment in immunotherapy change the future of treatment?
* Is there value in novel targeted therapies or will current treatments continue to dominate?
Strategic scoping and focus
Datamonitor key findings
CLINICAL PIPELINE OVERVIEW
Allergen immunotherapy dominates late-stage pipeline
Analysis by formulation demonstrates innovation in the pipeline
Late-stage discontinued development compounds
Epinastine nasal formulation (Inspire Pharmaceuticals)
Sublingual immunotherapies (Greer)
TARGET PRODUCT PROFILE
Telfast/Allegra (fexofenadine; Sanofi-Aventis)
Pivotal trial data for Telfast/Allegra
Nasonex (mometasone; Merck & Co.)
Pivotal trial data for Nasonex
Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN ALLERGIC RHINITIS
Trends in clinical trial endpoints
Allergy challenges tackle seasonal variations
Drug development guidelines in allergen immunotherapy
Typical allergic rhinitis clinical trials
Future developments in clinical trial design
INNOVATIVE EARLY-STAGE APPROACHES
Sublingual immunotherapy franchises
Novel targeted therapies
THE FUTURE OF TREATMENT IN ALLERGIC RHINITIS
Combination antihistamine/corticosteroid therapy
Sublingual shift in immunotherapy
To order this report:
Email: [email protected]
Intl: +1 805-652-2626